Brainsway

BWAY · TEL

$11.25−$0.19 (−1.66%)TodayMarket closed · Oct 23, 7:30 PM ET

Prev close $11.44

Latest news

Press releaseOct 19, 7:30 AM ETGlobe Newswire
BrainsWay Announces Strategic Collaboration with Inland Psychiatry Medical Group
NewsOct 13, 10:12 AM ETAvi Kapoor
Bumble, Fermi, Xtend AI Robotics And Other Big Stocks Moving Higher On Tuesday
Press releaseOct 13, 7:30 AM ETGlobe Newswire
BrainsWay Reports Rise in Favorable Accelerated Deep TMS™ Coverage to Over 70 Million Covered Lives
Press releaseSep 8, 7:30 AM ETGlobe Newswire
BrainsWay Reports Promising Pilot Study Results in Patients with Depression and Comorbid Early-Stage Alzheimer’s Disease Treated with Deep TMS™
Press releaseAug 27, 7:30 AM ETGlobe Newswire
BrainsWay Deep TMS™ Study Shows 70% Reduction in Patients Experiencing Suicidal Ideation
NewsAug 12, 7:54 AM ET
BrainsWay Q2 EPS $0.07 Misses $0.08 Estimate, Sales $17.107M Beat $16.497M Estimate
Press releaseAug 12, 7:30 AM ETGlobe Newswire
BrainsWay Reports Second Quarter 2026 Financial Results and Operational Highlights
Press releaseJul 29, 7:30 AM ETGlobe Newswire
BrainsWay to Report Second Quarter 2026 Financial Results on August 12, 2026
Press releaseJul 20, 7:30 AM ETGlobe Newswire
BrainsWay Announces Strategic Investment in Radial Health, Inc.
Press releaseJul 16, 7:30 AM ETGlobe Newswire
BrainsWay Announces Minority-Stake Investment in Sound Minds Behavioral
Press releaseJun 29, 7:30 AM ETGlobe Newswire
BrainsWay Presents Positive Data from Largest Real-World Study of Deep TMS™ in Patients with Comorbid PTSD and Major Depressive Disorder
Press releaseJun 22, 7:30 AM ETGlobe Newswire
BrainsWay Reports Favorable Coverage for Accelerated Deep TMS™ Rises to Over 57 Million Covered Lives
Press releaseJun 9, 7:30 AM ETGlobe Newswire
BrainsWay Presents First SWIFT™ Accelerated Deep TMS 12-Month Durability Data at Clinical TMS Society Annual Meeting
Press releaseMay 18, 7:30 AM ETGlobe Newswire
BrainsWay Announces Minority-Stake Investment in Hopemark Health
NewsMay 13, 9:46 AM ET
Full Transcript: BrainsWay Q1 2026 Earnings Call
NewsMay 13, 7:32 AM ET
BrainsWay Q1 EPS $0.06 Beats $0.05 Estimate, Sales $15.531M Beat $14.539M Estimate
Press releaseMay 13, 7:30 AM ETGlobe Newswire
BrainsWay Reports First Quarter 2026 Financial Results and Operational Highlights
NewsMay 13, 7:11 AM ET
Earnings Scheduled For May 13, 2026
Press releaseApr 29, 8:00 AM ETGlobe Newswire
BrainsWay to Report First Quarter 2026 Financial Results on May 13, 2026
Press releaseApr 15, 7:30 AM ETGlobe Newswire
BrainsWay Highlights Growing U.S. Payer Support for Nurse Practitioner-Administered Transcranial Magnetic Stimulation (TMS) Therapy
Press releaseApr 13, 8:00 AM ETGlobe Newswire
BrainsWay to Participate in the 25th Annual Needham Virtual Healthcare Conference
Press releaseMar 26, 7:30 AM ETGlobe Newswire
BrainsWay Completes Additional $6 Million Milestone-Based Investment in Neurolief Ltd. Following FDA Approval of Proliv™Rx System for MDD
NewsMar 24, 8:02 AM ETAvi Kapoor
Hesai Group, BitFuFu And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
NewsMar 24, 8:02 AM ETAvi Kapoor
Hesai Group, BitFuFu And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Press releaseMar 19, 7:30 AM ETGlobe Newswire
BrainsWay Completes Revenue-Based Milestone Investment into Axis Integrated Mental Health
NewsMar 11, 9:18 AM ETDylan Berman
BrainsWay Reports Q4 Earnings: Revenue Beat, Guidance Below Estimates
NewsMar 11, 7:31 AM ET
BrainsWay Q4 EPS $0.04, Inline, Sales $14.545M Beat $14.011M Estimate
Press releaseMar 11, 7:30 AM ETGlobe Newswire
BrainsWay Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
NewsMar 11, 7:11 AM ET
Earnings Scheduled For March 11, 2026
NewsMar 10, 2:01 PM ET
Uncovering Potential: BrainsWay's Earnings Preview
Press releaseMar 5, 9:30 AM ETPRNewswire
Anxiety Treatment Boom: GAD Therapies Poised for Multi-Billion Dollar Expansion
Press releaseMar 4, 7:30 AM ETGlobe Newswire
Landmark Data Validate BrainsWay's SWIFT™ Deep TMS, Beginning a New Era in Depression Treatment
Press releaseFeb 25, 8:00 AM ETGlobe Newswire
BrainsWay to Report Fourth Quarter and Full Year 2025 Financial Results on March 11, 2026
Press releaseFeb 23, 8:00 AM ETGlobe Newswire
BrainsWay to Participate in the Citi 2026 Unplugged MedTech and Life Sciences Access Day
Press releaseFeb 19, 7:30 AM ETGlobe Newswire
BrainsWay Announces New Minority-Stake Investment in Canadian Provider, BrainStim Health Inc.
NewsFeb 18, 7:39 AM ET
BrainsWay Notes Cigna's Evernorth Policy Shift Removing Prior Authorization For Transcranial Magnetic Stimulation, Effective March 2026; Highlights Access Expansion
Press releaseFeb 18, 7:30 AM ETGlobe Newswire
BrainsWay Reports Cigna's Evernorth Behavioral Health to Eliminate Prior Authorization Requirements for TMS Coverage, Accelerating Access to Care
NewsJan 26, 7:00 AM ET
What Analysts Are Saying About BrainsWay Stock
NewsNov 10, 10:03 AM ET
Insights into BrainsWay's Upcoming Earnings
NewsAug 14, 3:01 PM ET
Breaking Down BrainsWay: 4 Analysts Share Their Views

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

BrainsWay Announces Strategic Collaboration with Inland Psychiatry Medical Group

Bumble, Fermi, Xtend AI Robotics And Other Big Stocks Moving Higher On Tuesday

BrainsWay Reports Rise in Favorable Accelerated Deep TMS™ Coverage to Over 70 Million Covered Lives

BrainsWay Reports Promising Pilot Study Results in Patients with Depression and Comorbid Early-Stage Alzheimer’s Disease Treated with Deep TMS™

BrainsWay Deep TMS™ Study Shows 70% Reduction in Patients Experiencing Suicidal Ideation

BrainsWay Q2 EPS $0.07 Misses $0.08 Estimate, Sales $17.107M Beat $16.497M Estimate

BrainsWay Reports Second Quarter 2026 Financial Results and Operational Highlights

BrainsWay to Report Second Quarter 2026 Financial Results on August 12, 2026

BrainsWay Announces Strategic Investment in Radial Health, Inc.

BrainsWay Announces Minority-Stake Investment in Sound Minds Behavioral

BrainsWay Presents Positive Data from Largest Real-World Study of Deep TMS™ in Patients with Comorbid PTSD and Major Depressive Disorder

BrainsWay Reports Favorable Coverage for Accelerated Deep TMS™ Rises to Over 57 Million Covered Lives

BrainsWay Presents First SWIFT™ Accelerated Deep TMS 12-Month Durability Data at Clinical TMS Society Annual Meeting

BrainsWay Announces Minority-Stake Investment in Hopemark Health

Full Transcript: BrainsWay Q1 2026 Earnings Call

BrainsWay Q1 EPS $0.06 Beats $0.05 Estimate, Sales $15.531M Beat $14.539M Estimate

BrainsWay Reports First Quarter 2026 Financial Results and Operational Highlights

Earnings Scheduled For May 13, 2026

BrainsWay to Report First Quarter 2026 Financial Results on May 13, 2026

BrainsWay Highlights Growing U.S. Payer Support for Nurse Practitioner-Administered Transcranial Magnetic Stimulation (TMS) Therapy

BrainsWay to Participate in the 25th Annual Needham Virtual Healthcare Conference

BrainsWay Completes Additional $6 Million Milestone-Based Investment in Neurolief Ltd. Following FDA Approval of Proliv™Rx System for MDD

Hesai Group, BitFuFu And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Hesai Group, BitFuFu And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

BrainsWay Completes Revenue-Based Milestone Investment into Axis Integrated Mental Health

BrainsWay Reports Q4 Earnings: Revenue Beat, Guidance Below Estimates

BrainsWay Q4 EPS $0.04, Inline, Sales $14.545M Beat $14.011M Estimate

BrainsWay Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

Earnings Scheduled For March 11, 2026

Uncovering Potential: BrainsWay's Earnings Preview

Anxiety Treatment Boom: GAD Therapies Poised for Multi-Billion Dollar Expansion

Landmark Data Validate BrainsWay's SWIFT™ Deep TMS, Beginning a New Era in Depression Treatment

BrainsWay to Report Fourth Quarter and Full Year 2025 Financial Results on March 11, 2026

BrainsWay to Participate in the Citi 2026 Unplugged MedTech and Life Sciences Access Day

BrainsWay Announces New Minority-Stake Investment in Canadian Provider, BrainStim Health Inc.

BrainsWay Notes Cigna's Evernorth Policy Shift Removing Prior Authorization For Transcranial Magnetic Stimulation, Effective March 2026; Highlights Access Expansion

BrainsWay Reports Cigna's Evernorth Behavioral Health to Eliminate Prior Authorization Requirements for TMS Coverage, Accelerating Access to Care

What Analysts Are Saying About BrainsWay Stock

Insights into BrainsWay's Upcoming Earnings

Breaking Down BrainsWay: 4 Analysts Share Their Views